While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Biocon Biologics and Viatris co-developed the products
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Second interchangeable biosimilar product approved by agency
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Over 61 per cent of pharmacists stated that they aim to improve their knowledge and medical skills while 76 per cent collaborated with healthcare players to improve the outcome for their patients
Investment of Rs 235 crores to add 411 beds in the next 18 months
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
